Compare iShares MSCI Indonesia ETF (EIDO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 41.4× iShares MSCI Indonesia ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EIDO | ZBH | |
|---|---|---|
Market Cap | $409.22M | $16.95B |
Volume | 879,527 | 2,505,240 |
52-Week High | $19.22 | $103.98 |
52-Week Low | $10.80 | $79.58 |
Typical Hold Time | 76 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.67, down 1.6% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF's financial ratios are not disclosed in available data, but recent news highlights its exposure to Indonesian equities and a challenging technical downtrend. Trading volume remains active, though recent sessions show a decline from average levels.
The outlook for EIDO is cautious due to weak price action and sector concentration risks, with limited upside from low earnings growth. Key risks include dependence on financials and commodity markets, while potential opportunities may arise from seasonal trends or valuation rebounds if investor sentiment improves.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
